Quantum-Si Announces New Manuscript Demonstrating the Value of Single-molecule Protein Sequencing to Aid in Identifying New Cancer Treatment Strategies

Key Terms

single-molecule protein sequencing medical

Single-molecule protein sequencing is a laboratory method that reads the exact order of building blocks in a single protein molecule, similar to reading letters in a word rather than averaging many copies. For investors it matters because it promises far more sensitive and precise detection of disease markers, faster drug discovery and highly personalized diagnostics, which could create new markets or disrupt existing lab testing and therapeutics businesses.

cohesin complex medical

A cohesin complex is a group of proteins that acts like a molecular clamp, holding duplicated DNA strands together and helping fold and organize the genome so cells divide and read genes correctly. Investors should care because errors or changes in cohesin can drive cancers and inherited disorders, making it a target for drugs, diagnostics, and genetic tests that can influence the value of biotech and pharmaceutical companies.

saccharomyces cerevisiae medical

Saccharomyces cerevisiae is a species of yeast long used as a microscopic workhorse in fermentation and biotechnology — like a tiny factory that converts sugars into alcohol, carbon dioxide, or other useful molecules. Investors should care because this organism is central to industries from brewing and baking to bio-manufacturing and pharmaceuticals; advances in how it is used or engineered can change production efficiency, costs, product pipelines, and therefore company value.

dominant-negative phenotype medical

A dominant-negative phenotype occurs when a mutated gene produces a faulty protein that not only loses its normal function but also interferes with the normal protein from the healthy gene, like a broken gear that jams the whole machine. For investors, this matters because such mutations can complicate drug development and therapy strategies, alter disease severity, and influence the value of diagnostics or treatments aimed at correcting or bypassing the disruption.

genome instability medical

Genome instability is the tendency of an organism’s complete set of genetic instructions to accumulate errors, breaks or rearrangements over time — like repeated typos and torn pages in a reference manual that guide cell behavior. For investors, it matters because high instability can drive disease progression, create measurable biomarkers, affect the durability and safety of therapies, and influence regulatory decisions and commercial prospects for diagnostics and treatments.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BRANFORD, Conn.--(BUSINESS WIRE)-- Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a proteomics company redefining protein analysis through single-molecule protein sequencing, today announced a new manuscript available via pre-print on bioRxiv from researchers out of the University of British Columbia and the B.C. Cancer Research Institute.

In the pre-print titled “Heterologous expression of the human cohesin complex in Saccharomyces cerevisiae results in a dominant-negative phenotype”, the researchers expressed key human chromosome‑organizing proteins (called cohesins) in yeast cells. They hypothesized that the human cohesins were forming complexes and disrupting the activity of endogenous yeast cohesins. This matters for cancer drug development because problems with cohesin can drive genome instability in tumors, pointing to new ways to target cancer cells. Quantum-Si’s single‑molecule protein sequencing was critical to the study because it provided direct, unbiased data demonstrating that human and yeast cohesin proteins physically assemble into the same complexes—something conventional antibodies and assays could not fully resolve.

“We are excited to see the first manuscript published by international researchers,” said Jeff Hawkins, President and Chief Executive Officer of Quantum-Si. “In this study, single‑molecule protein sequencing enabled the researchers at University of British Columbia and B.C. Cancer Research Institute to directly identify hybrid cohesin complexes, demonstrating the value of our technology as a foundational tool for mechanistic biology research and therapeutic discovery.”

A link to the bioRxiv pre-print can be found here.

About Quantum-Si Incorporated

Quantum-Si is transforming proteomics with a benchtop platform that brings single-molecule protein analysis to every lab, everywhere. The Company’s platform enables real-time kinetic-based detection and allows researchers to move beyond traditional, multistep workflows and directly access dynamic, functional protein insights with unparalleled resolution. By making protein analysis simpler, faster, and more informative, Quantum-Si is accelerating proteomic discoveries to improve the way we live. Learn more at quantum-si.com or follow us on LinkedIn or X.

Forward Looking Statements

This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. The actual results of the Company may differ from its expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company’s expectations with respect to future performance and development and commercialization of products, services and applications, its anticipated cash runway, the anticipated timing of product launches and product capabilities (including Proteus), investor confidence in Quantum-Si and our strategic roadmap, and any financial guidance. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward-looking statements. Many of these factors are outside the Company’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the inability to maintain the listing of the Company’s Class A common stock on The Nasdaq Stock Market; the ability of the Company to grow and manage growth and retain its key employees; the Company’s ongoing leadership transitions and succession planning; changes in applicable laws or regulations; the ability of the Company to raise financing in the future; the success, cost and timing of the Company’s product development and commercialization activities, including the use and benefit of artificial intelligence in these and other activities; the commercialization and adoption of the Company’s existing products and the success of any product the Company may offer in the future, including Proteus; the potential attributes and benefits of the Company’s commercialized Platinum protein sequencing instruments and kits and the Company’s other products (including Proteus) once commercialized; the Company’s ability to obtain and maintain regulatory approval for its products, and any related restrictions and limitations of any approved product; the Company’s ability to identify, in-license or acquire additional technology; the Company’s ability to maintain its existing lease, license, manufacture and supply agreements; the Company’s ability to compete with other companies currently marketing or engaged in the development or commercialization of products and services that serve customers engaged in proteomic analysis, many of which have greater financial and marketing resources than the Company; the size and growth potential of the markets for the Company’s products and services, and its ability to serve those markets once commercialized, either alone or in partnership with others; the Company’s estimates regarding future expenses, future revenue, capital requirements and needs for additional financing; the Company’s financial performance; the Company's defense and initiation of litigation matters; and other risks and uncertainties described under “Risk Factors” in the Company’s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q and in the Company’s other filings with the SEC. The Company cautions that the foregoing list of factors is not exclusive. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260409322122/en/

Investor and Media
Jeff Keyes
Chief Financial Officer
ir@quantum-si.com

Source: Quantum-Si Incorporated